European Commission logo
English English
CORDIS - EU research results


Project description

Biological structures come into clear view without the need for labeling

Cell imaging techniques have advanced tremendously over the last few decades, providing high-resolution real-time information about numerous biological processes. One important way scientists have been able to capture processes that have occurred or tag molecules of interest is with the use of fluorescent labels. However, that technique can add time, money and obviously a modification to native molecules and structures. The EU-funded LABELFREE project is preparing to put its phi-SCAT system for label-free high-contrast imaging on the market as a valuable alternative for many applications. The commercialisation plan includes making it available as a stand-alone system and potentially integrated into existing microscope systems for maximum impact and flexibility.


We will launch phi-SCAT, a novel imaging technology, which uniquely allows for label-free imaging of biological structures of interest. We will do this by productizing the interferometric scattering technology that was invented in course of the Chromavision FET-OPEN project. Proof-of-concept data has been obtained in the FET-OPEN project, and proved the technology’s value, complementary to existing imaging methods that are either low contrast or depend on fluorescent labels. The project will focus on the steps needed for the market launch of this novel technology. We will follow two parallel trajectories for exploitation: firstly we will implement and launch a phi-SCAT module on our existing C-Trap single-molecule analysis product line. Secondly we will approach potential licensing partners for implementation of the phi-SCAT technology on existing microscope platforms.
This project will result in a valuable valorisation of one of the most significant innovations that stemmed from the Chromavision FET-OPEN project. Besides significant positive impact on our C-Trap product line’s turnover and gross margin, the application of this more effective microscopy method in academic and pharmaceutical research will have profound impact on the understanding of key biological processes and contribute greatly to optimization of the drug discovery process

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 100 000,00
1105 AG Amsterdam

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 106 562,50